Daye Review: What Women Should Know About This Gynecological Health Brand

What Is Daye and How Does It Work?

Daye is a gynecological health company built around the idea that period pain and vaginal health have been chronically under-researched and under-served. Founded in London in 2018 by Valentina Milanova, it sells direct to consumers via its website and offers a subscription model for regular tampon delivery alongside diagnostic add-ons.

The business model is straightforward: you order online, products arrive by post, and diagnostic tests are completed at home using self-collection kits. Results are delivered digitally, sometimes with a follow-up consultation option. There is no brick-and-mortar clinic.

Its product range falls into three categories:

• CBD-infused tampons designed to reduce menstrual pain through transmucosal cannabidiol absorption
• Vaginal microbiome testing that sequences vaginal bacteria and provides a report on community state types linked to infection risk and fertility
• At-home STI screening covering common infections including chlamydia, gonorrhea, HIV, and syphilis

Daye positions itself as a science-led brand. That claim deserves scrutiny, and this review applies it.

The Science Behind CBD Tampons: What the Evidence Actually Shows

CBD tampons are Daye's most distinctive and most debated product. Each tampon contains 100 mg of broad-spectrum CBD coated on the applicator and absorbed transvaginally. The proposed mechanism is local anti-inflammatory and antispasmodic action on uterine smooth muscle, bypassing hepatic first-pass metabolism.

Does Transmucosal CBD Absorption Actually Work?

The vaginal mucosa is highly vascularized and capable of absorbing lipophilic compounds, a principle well-established in gynecological drug delivery for hormones such as estradiol and progesterone. Preclinical and pharmacokinetic data support the idea that vaginal drug delivery can achieve higher local tissue concentrations than oral routes for certain molecules.

Whether CBD specifically achieves meaningful uterine tissue concentrations via this route in humans has not been established in a published clinical trial as of this writing. Daye has cited an internal pilot study, but peer-reviewed, placebo-controlled data on its specific product are not yet available in indexed literature. That is a meaningful evidence gap, and you should weigh it accordingly.

What We Know About CBD and Dysmenorrhea

Dysmenorrhea affects an estimated 50 to 90 percent of women of reproductive age, making it one of the most prevalent gynecological conditions globally. Standard first-line treatments include NSAIDs (ibuprofen, naproxen) and combined oral contraceptives, both of which have strong randomized controlled trial support.

CBD's anti-inflammatory properties are real. Cannabidiol inhibits COX-2 enzymes and modulates endocannabinoid receptor signaling, mechanisms relevant to uterine cramping. A 2020 review in the Journal of Clinical Medicine noted that cannabinoids show biological plausibility for pain modulation, but the authors found insufficient human trial data to recommend cannabis-based products for gynecological pain.

Daye is conducting an observational study through a partnership with NHS trusts. Until results are published and peer-reviewed, the CBD tampon sits in the category of "biologically plausible, clinically unproven." That does not make it useless, but it does mean you should not rely on it as a substitute for proven dysmenorrhea treatment if your pain is severe.

Women With Endometriosis: A Specific Note

Endometriosis affects approximately 10 percent of reproductive-age women and is one of the leading causes of severe dysmenorrhea. Women with endometriosis are among Daye's most vocal users based on community feedback, understandably so given how poorly existing treatments serve them.

The endocannabinoid system is dysregulated in endometriotic tissue, and there is genuine scientific interest in cannabinoid-based approaches for endometriosis pain. A 2017 paper in PLOS ONE found endocannabinoid receptor expression altered in endometriotic lesions, suggesting a target. But translating receptor biology into a proven treatment requires clinical trials, which do not yet exist for Daye's product specifically.

If you have endometriosis, discuss any CBD product with your OB-GYN or specialist before starting, particularly if you are also taking hormonal therapies, immunosuppressants, or are being evaluated for surgery.

Vaginal Microbiome Testing: Clinical Utility and Limitations

This is where Daye's offering has clearer real-world value. The vaginal microbiome test sequences bacterial communities from a self-collected swab and categorizes them into community state types (CSTs), a classification framework developed from landmark microbiome research.

What Community State Types Mean for You

A foundational 2011 paper by Ravel et al. In PNAS established five dominant vaginal community state types. CST I, II, III, and V are each dominated by different Lactobacillus species and associated with lower infection risk. CST IV is characterized by low Lactobacillus abundance and high microbial diversity, linked to higher rates of bacterial vaginosis (BV), preterm birth risk, and HIV acquisition.

Understanding your CST has practical implications:

• If you have recurrent BV, knowing whether you have a CST IV profile helps explain why standard antibiotic courses keep failing and may support the case for extended suppressive therapy or boric acid adjuncts.
• If you are trying to conceive, emerging data suggest that CST IV profiles may be associated with higher rates of implantation failure in IVF cycles, as discussed in a 2019 paper in Fertility and Sterility.
• If you are in perimenopause, declining estrogen reduces Lactobacillus dominance naturally, shifting many women toward CST IV-like profiles. This contributes to genitourinary syndrome of menopause (GSM) symptoms including dryness and recurrent infections. Vaginal microbiome testing in this life stage may help distinguish estrogen-related dysbiosis from true infection.

What the Test Does Not Do

The microbiome test is not a diagnostic test for STIs. It does not replace cervical cancer screening (the Pap smear or HPV co-test). It will not detect chlamydia, gonorrhea, or trichomonas. It cannot diagnose candidiasis definitively. Its report provides community-level data, not a clinical diagnosis, and any treatment decisions should involve a qualified clinician reviewing the results in the context of your full history.

Daye provides a report with explanations, but the interpretive support is variable in depth. The report alone is not a substitute for a consultation.

At-Home STI Screening: How It Compares to Standard Testing

Daye's STI screening covers a panel that typically includes chlamydia, gonorrhea, HIV (4th-generation Ag/Ab combo), and syphilis. Tests are processed in UKAS-accredited laboratories, which is a meaningful quality signal for UK users.

Chlamydia remains the most commonly diagnosed STI in England, with young women aged 15 to 24 carrying the highest diagnosed rates. At-home self-collected testing has been validated against clinician-collected samples for chlamydia and gonorrhea detection. A Cochrane review (Lunny et al., 2021) found that self-sampling for STIs performed comparably to clinician-collected samples for sensitivity and specificity.

The practical case for at-home STI testing is access. Many women delay or avoid clinic visits due to stigma, time constraints, or geography. If the result is positive, Daye's pathway connects users to partner services for treatment. The STI testing piece of Daye's offering sits on solid evidence ground.

A Note on Gonorrhea Testing Accuracy

Self-collected vaginal swabs have slightly lower sensitivity for gonorrhea than cervical swabs collected by a clinician, particularly for pharyngeal or rectal sites. If you have symptoms, a recent high-risk exposure, or engage in receptive anal or oral sex, a clinic-based test with multiple site sampling is preferable to any home kit.

What Does Daye Prescribe?

Daye does not currently operate as a prescribing platform. It does not issue prescriptions for contraception, antibiotics, antifungals, or hormonal therapies directly. This distinguishes it from telehealth prescribers such as Wisp or Hey Doctor. Daye's model is diagnostic and product-based, with referral pathways for treatment rather than in-house prescribing.

This is worth knowing clearly: if you receive a positive STI result or a microbiome report suggesting BV, you will need to go to your GP, sexual health clinic, or a separate telehealth prescriber for treatment. Daye does not close that loop itself.

How Much Does Daye Cost?

Daye's pricing sits at a premium relative to conventional alternatives.

| Product | Approximate Cost (GBP) | |---|---| | CBD tampons (12-pack) | £14 to £18 | | Vaginal microbiome test | £115 to £139 | | STI screening panel | £79 to £149 depending on panel | | Subscription discount | Approximately 15% |

For comparison, NHS sexual health clinics offer free STI testing to UK residents. Free testing is also available via SH:24 and other NHS-commissioned at-home services. The Daye STI test's value proposition is primarily speed and convenience, not clinical superiority.

The microbiome test has no direct NHS equivalent because routine microbiome sequencing is not part of standard NHS care. Whether that test is worth £115 to £139 depends entirely on your clinical context. For a woman with recurrent BV who has failed multiple antibiotic courses, the information may genuinely change management. For a woman with no symptoms and no specific concern, the clinical return on investment is less clear.

Is Daye Legit? Regulatory Status and Quality Markers

Daye operates legally in the UK. Its CBD products are sold as wellness products, not medicines, which means they are not subject to MHRA medicines regulation. This is the same regulatory position as all CBD products in the UK. It does not mean the products are unsafe, but it does mean the efficacy bar they must meet for sale is lower than for a licensed medicine.

Its laboratory testing is conducted through UKAS-accredited partners, which is a genuine quality marker. The company has published a research pipeline page and has disclosed IRB-level partnerships with NHS institutions, though peer-reviewed publications from those collaborations are still awaited.

A useful framework for evaluating Daye against the evidence:

Strong evidence base: At-home STI testing (self-collection validated by Cochrane), vaginal microbiome CST classification (peer-reviewed science, though clinical utility in healthy asymptomatic women is less established).

Biologically plausible, clinically unproven: CBD tampons for menstrual pain. The mechanism is credible; the product-specific human trial data are not yet published.

Regulatory gap to understand: CBD is not a licensed medicine in the UK or EU. Daye cannot make medicinal claims, and you should read any efficacy language on its site with that context in mind.

Daye vs. Alternatives: How It Stacks Up by Category

For STI Testing

• SH:24 / NHS at-home postal testing: Free, validated, slightly longer turnaround in some areas
• Superdrug Online Doctor: Paid, fast, prescription-capable
• Daye: Paid, UKAS-accredited, no prescription follow-through

For Vaginal Microbiome Testing

• Evvy (US-based): Metagenomic sequencing with a broader panel, not available in UK
• Juno Bio (UK): Direct competitor, similar CST-based reporting, slightly lower price point in some configurations
• Daye: 16S rRNA sequencing, integrated with their product system

For Menstrual Pain

• Ibuprofen 400 mg three times daily from the first day of menstruation: The best-evidenced pharmacological option for primary dysmenorrhea, per ACOG guidance
• Combined oral contraceptives: Effective for both primary dysmenorrhea and endometriosis-associated pain
• Daye CBD tampons: No head-to-head trial data versus NSAIDs or hormonal therapy

Who Daye Is Right For, and Who It Is Not

Life Stages and Conditions Where Daye May Add Value

Reproductive years (18 to 40): Women with recurrent BV who want microbiome-level insight, women with primary dysmenorrhea willing to trial CBD alongside (not instead of) proven treatments, and women who want accessible STI screening without a clinic visit.

Trying to conceive: Vaginal microbiome data may be relevant if you are experiencing implantation failure or recurrent miscarriage. This should be reviewed with a reproductive endocrinologist, not interpreted in isolation from a report.

Perimenopause: The microbiome test may help clarify whether vaginal symptoms stem from dysbiosis, GSM, or both. However, if you have GSM symptoms, vaginal estrogen remains the most effective and evidence-based treatment, and Daye does not prescribe it.

Who Should Not Rely on Daye Alone

• Women with severe dysmenorrhea or suspected endometriosis: You need a clinician-guided workup, not an OTC CBD product.
• Women with active STI symptoms: At-home testing delays are not appropriate when symptoms are present. Go to a sexual health clinic.
• Women who are pregnant: See the section below.
• Women outside the UK: Availability varies and some products do not ship internationally.

Pregnancy, Lactation, and CBD: A Required Safety Discussion

Daye's CBD tampons are not for use during pregnancy. This is not a precautionary hedge; it reflects a genuine evidence gap with meaningful risk implications.

The FDA has stated clearly that there is no safe level of cannabis or CBD use established during pregnancy. Animal studies show that CBD exposure during critical developmental windows affects fetal brain development. Human data are limited, but the precautionary standard is abstinence.

ACOG's Committee Opinion on Marijuana Use During Pregnancy and Lactation recommends that women be counseled to discontinue marijuana and cannabinoid products before attempting conception and throughout pregnancy and breastfeeding. The transfer of CBD into breast milk has been documented, though the clinical significance for the nursing infant is not fully characterized.

If you become pregnant while using Daye's CBD tampons, stop using them and inform your obstetric provider. The diagnostic tests (microbiome, STI screening) carry no pregnancy-related risk and remain useful during pregnancy, particularly STI screening which is recommended as part of prenatal care.

Daye's CBD products require no prescription and have no formal contraception requirement, but any woman of reproductive age using them should be aware that pregnancy risk means stopping immediately upon a positive pregnancy test or when attempting to conceive.

Daye Reviews: What Real Users Report

User sentiment skews positive for the convenience of the diagnostic tests and the customer experience. Common themes in reviews:

• The microbiome report is detailed but can feel difficult to act on without professional guidance
• CBD tampons receive mixed efficacy reviews; some users report meaningful pain reduction, others notice no effect
• The subscription model is straightforward to manage
• Price is the most common barrier cited

Critical reviews frequently note that positive STI results route users back to external services, which some find disjointed for a company positioning itself as a comprehensive gynecological health platform.

No independent, peer-reviewed analysis of user outcome data from Daye's customer base has been published. Reviews on Trustpilot and similar platforms are self-selected and should be read as experiential signals, not efficacy data.

The Bottom Line on Daye's Business Model

Daye occupies a genuine market gap: gynecological health diagnostics delivered conveniently, with a focus on conditions that have historically received inadequate clinical attention. The business model is sound. The diagnostic products have real utility in the right clinical context.

The CBD tampon line is the part of the business that requires the most scrutiny from a evidence standpoint. The mechanism is credible, the product is legal and likely safe for non-pregnant adults, but the specific efficacy claim has not been validated in a published randomized controlled trial. Women with significant menstrual pain should treat CBD tampons as a complement to proven treatments, not a replacement.

The company's long-term credibility will depend on whether its NHS partnerships produce peer-reviewed publications. Until then, the strongest parts of Daye's offering are the STI testing and the microbiome data, particularly for women with recurrent BV, fertility concerns, or perimenopausal vaginal symptoms who want more information than a standard clinic visit provides.